产品
编 号：F743562
分子式：C19H19N3O2
分子量：321.37
分子式：C19H19N3O2
分子量：321.37
产品类型
规格
价格
是否有货
结构图
CAS No: 1254032-16-0
产品详情
生物活性：
(rac)-AR-13503 ((rac)-AR-13324 M1 metabolite) is the isoform of AR-13503 (HY-12798C). AR-13503 a ROCK/PKC inhibitor, inhibiting angiogenesis and enhancing retinal pigment epithelium (RPE) permeability. AR-13503 also inhibits the formation of aberrant neovascularization (NV) in oxygen-induced retinopathy (OIR) model in mice.
体内研究：
AR-13503 (1.25 mg/kg；腹腔注射；每天 1 次，共 5 天) 与 Aflibercept (HY-108801) 有协同作用，显著降低了异常新生血管 (NV) 形成。Animal Model:Oxygen-induced retinopathy (OIR) mice model (C57BL/6; 7-days-old)
Dosage:1.25 mg/kg
Administration:Intraperitoneal injection; once daily for 5 days
Result:The combination group had a greater (~75%) reduction in NV than Aflibercept alone (~55%).
体外研究：
AR-13503 (16 小时) 抑制人脐静脉内皮细胞 (HUVEC) 管的形成，IC50 为 21 nM。AR-13503 (400 nM; 5 天) 以剂量依赖的方式减少脉络膜的发芽面积。AR-13503 (400 nM; 2 周) 以剂量依赖的方式增强猪主要 RPE 屏障功能。
(rac)-AR-13503 ((rac)-AR-13324 M1 metabolite) is the isoform of AR-13503 (HY-12798C). AR-13503 a ROCK/PKC inhibitor, inhibiting angiogenesis and enhancing retinal pigment epithelium (RPE) permeability. AR-13503 also inhibits the formation of aberrant neovascularization (NV) in oxygen-induced retinopathy (OIR) model in mice.
体内研究：
AR-13503 (1.25 mg/kg；腹腔注射；每天 1 次，共 5 天) 与 Aflibercept (HY-108801) 有协同作用，显著降低了异常新生血管 (NV) 形成。Animal Model:Oxygen-induced retinopathy (OIR) mice model (C57BL/6; 7-days-old)
Dosage:1.25 mg/kg
Administration:Intraperitoneal injection; once daily for 5 days
Result:The combination group had a greater (~75%) reduction in NV than Aflibercept alone (~55%).
体外研究：
AR-13503 (16 小时) 抑制人脐静脉内皮细胞 (HUVEC) 管的形成，IC50 为 21 nM。AR-13503 (400 nM; 5 天) 以剂量依赖的方式减少脉络膜的发芽面积。AR-13503 (400 nM; 2 周) 以剂量依赖的方式增强猪主要 RPE 屏障功能。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备